Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts. (2021)
Attributed to:
Precision Medicine in Crohn's Disease and Ulcerative Colitis: Predicting Disease Flare and Disease progression
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/ecco-jcc/jjab100
PubMed Identifier: 34089587
Publication URI: http://europepmc.org/abstract/MED/34089587
Type: Journal Article/Review
Volume: 15
Parent Publication: Journal of Crohn's & colitis
Issue: 12
ISSN: 1873-9946